Clinical Characteristics and Treatment of Chest Tightness Variant Asthma
NCT ID: NCT04322422
Last Updated: 2020-05-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
300 participants
INTERVENTIONAL
2020-06-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Characteristics, Treatment and Prognosis of Chest Tightness Variant Asthma
NCT03237221
The Study About the Identification of Treatable Traits of Severe Asthma and the Construction of Personalized Treatment System
NCT07136025
Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )
NCT00968201
Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test
NCT01759472
Acute Montelukast in Asthma
NCT01011452
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ICS/LABA plus Montelukast
Inhaled corticosteriod/long-acting beta-agonist plus Montelukast
Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma; Montelukast is benefitial for allergic disease
ICS/LABA only
Inhaled corticosteriod/long-acting beta-agonist only
Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inhaled corticosteriod/long-acting beta-agonist plus Montelukast
Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma; Montelukast is benefitial for allergic disease
Inhaled corticosteriod/long-acting beta-agonist only
Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. the age of more than 14 and less 80 years old, gender and ethnicity are not limited;
3. the duration time was more than 6 months,and chest tightness was the only complaint, without breathing, short of breath, chronic cough;
4. no wheezing;
5. a diagnosis of asthma supported by one or more other characteristics:
* bronchial provocation test positive;
* improvement in forced expiratory volume at one second (FEV1) of more than 12% and 200 mL after inhaled salbutamol;
* variability in diurnal peak expiratory flow (PEF) of more than 10% for one day during one week.
6. bronchodilator and glucocorticoid treatment is effective;
7. exclude the following diseases by the corresponding doctors: coronary heart disease, myocarditis, heart failure, gastroesophageal reflux disease(GERD), neuromuscular disease, and mental disease.
Exclusion Criteria
2. patients with chronic obstructive pulmonary disease, interstitial pneumonia, active tuberculosis, community acquired pneumonia, lung cancer, bronchiectasis, cor pulmonale, pulmonary embolism, and accompanied with serious systematic disease (such as coronary heart disease, myocarditis, heart failure, gastroesophageal reflux disease, neuromuscular disease, etc);
3. history of drug abuse, alcohol abuse or anesthesia or with a history of mental illness (schizophrenia, obsessive-compulsive disorder, depression) and against personality, motivation, suspicious, or other emotional or mental issues that may affect participation in the study;
4. taking part in other drug clinical trial project, or drop out less than 3 months;
5. during pregnancy, lactation women;
6. obvious abnormal of High Resolution CT.
14 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Chao-Yang Hospital
Beijing, Beijing Municipality, China
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Xinqiao Hospital，Third Military Medical University
Chongqing, Chongqing Municipality, China
The Second Affiliated Hospital，Fujian Medical University
Fuzhou, Fujian, China
Nanfang Hospital, Nanfang Medical University
Guangzhou, Guangdong, China
The First Affiliated Hospital,Guangzhou Medical University
Guangzhou, Guangdong, China
People's Hospital of Shenzhen
Shenzhen, Guangdong, China
Affiliated Hospital,Zhanjiang Medical College
Zhanjiang, Guangdong, China
Guizhou Provincial People's Hospital
Guiyang, Guizhou, China
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology
Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Xiangya Hospital of Central South University
Changsha, Hunan, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
The Central Hospital of Shenyang Military
Shenyang, Liaoning, China
The First Affiliated Hospital, China Medical University
Shenyang, Liaoning, China
Xijing Hospital
Xi'an, Shaanxi, China
Qilu Hospital, Shandong University
Jinan, Shandong, China
Shandong Provincal Hospital
Jinan, Shandong, China
Qingdao Municipal Hospital
Qingdao, Shandong, China
Weifang Asthma Hospital
Weifang, Shandong, China
Yantai liuhuanding Hospital
Yantai, Shandong, China
Changhai Hospital, Second Military Medical University
Shanghai, Shanghai Municipality, China
No.1 Hospital, Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China
Ruijin Hospital, Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China
Tongji Hospital, Tongji University
Shanghai, Shanghai Municipality, China
Xinhua Hospital, Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
West China Hospital，Sichuan University
Chengdu, Sichuan, China
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Sir Run Run Shaw hospital, College of Medicine，Zhejiang University
Hangzhou, Zhejiang, China
Huzhou Central Hospital
Huzhou, Zhejiang, China
The Second Affiliated Hospital,Wenzhou Medical University
Wenzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Huahao Shen
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Nanshan Zhong
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTVA-ZJU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.